Investors Menu

Financials

We are an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Download item year list
Date Download Description

We enable healthier lives, everywhere, every day As the leader in women’s health, we deliver life-changing and life-saving diagnostic, detection, and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

Genius 3D exam
Genius™ 3D™ exam

The Genius™ 3D Mammography™ exam1 detects 20-65% more breast cancers compared to 2D mammography alone.2

Affirm Prone Biopsy System
Affirm® Prone Biopsy System

TheSuperior biopsy imaging using Genius 3D technology. Improved workflow results in faster procedures and an enhanced patient experience.

Horizon DXA Bone Densitometry
Horizon™ DXA Bone Densitometry

Provides high-quality clinical images that reveal the smallest fractures at the earliest stage — helping to keep patients strong and healthy. Horizon™ was designed to assess osteoporosis, obesity and aortic calcifications.

NovaSure for AUB
NovaSure® for AUB

NovaSure endometrial ablation for abnormal uterine bleeding (AUB) can dramatically improve a woman’s comfort, confidence and quality of life. It is a safe, simple solution used by more than 3 million women since 2001.

MyoSure Hysteroscopic Tissue Removal
MyoSure® Hysteroscopic Tissue Removal

The MyoSure procedure enables fast, safe removal of fibroids, polyps and retained products of conception in less than 15 minutes — without having to make a single incision. It enables convenient removal of intrauterine pathology under direct visualization.

Panther System
Panther® System

Offers best-in-class automation and workflow for molecular diagnostics, giving laboratories greater freedom and flexibility with true walkaway processing and random access sampling. Delivers a broad menu of the most sensitive, accurate, and precise assays.

Aptima Molecular Diagnostic Assays
Aptima® Molecular Diagnostic Assays

Hologic developed the first FDA-cleared nucleic acid test for infectious diseases over 30 years ago. Today, our state-of-the-art Aptima assays quickly identify diseases like chlamydia, gonorrhea, HPV & trichomoniasis at early stages, often within days of infection.

ThinPrep Pap test
ThinPrep® Pap test

Cervical cancer was the #1 cancer killer of women prior to the introduction of Pap screening, now it’s #14.3 Hologic’s ThinPrep liquid-based cytology test has revolutionized cervical cancer screening and is the leading cervical specimen collection product in the world.

Brevera Breast Biopsy System
Brevera® Breast Biopsy System

The Brevera® breast biopsy system with CorLumina® imaging technology is the world’s first and only solution to combine tissue acquisition, real-time imaging, verification and advanced post-biopsy handling—all in one, integrated system.

Fluoroscan
Fluoroscan® InSight™ Mini C-arm Extremities Imaging System

Provides excellent image quality and system versatility for all extremity imaging needs. The system is designed to help minimize radiation by preventing patient and surgeon exposure to the unused area of the detector.

SARS-CoV-2 Tests
SARS-CoV-2 Tests

To help fight COVID-19, Hologic developed the Panther Fusion® and Aptima SARS-CoV-2 assays, and scaled up to produce 1.5 million tests a week. The tests run on the world’s largest installed base of more than 2,800 high-throughput instruments.

1. The Genius™ exam is only available on the Hologic® 3D Mammography™ system. Please visit www.MyGenius3D.com/pro for more information. 2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. 3. https://www.report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76

Financial Fast Facts

Revenue Highlights 3Q20

Revenue Highlights 1Q20

Financial Overview 3Q20

Financial Overview 1Q20

Financial Guidance for Fourth Fiscal Quarter 2020

Financial-Guidance

Capital Deployment Priorities

Business development

  • Tuck-in acquisitions
  • Accretive to revenue, EPS growth rates
  • Attractive ROIC
  • Leveraging existing sales channels

Opportunistic share repurchases

Net Debt & Leverage Ratio3

Net Debt & Leverage Ratio

Revenue & CC Growth Rates

Revenue & CC Growth Rates

2019 Divisional Revenue by Geography

2019 Divisional Revenue by Geography

Non-GAAP EPS

Non-GAAP EPS

Non-GAAP Net Margin %

% Net Margin

ROIC

ROIC

1. Includes contributions from divested blood screening business. Excluding blood, Diagnostics sales increased 80.1% on a reported basis, or 80.8% in constant currency.
2. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
3. Core Revenue excludes Blood Screening and Medical Aesthetics.
4. Organic Revenue excludes divested Blood Screening and Medical Aesthetics businesses, and acquired SSI business.
5. Divestiture of Medical Aesthetics business was completed on 12/30/19.




Quicklinks